Oxogluric acid API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Oxogluric acid is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Oxogluric acid or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Oxogluric acid API 328-50-7?

Description:
Here you will find a list of producers, manufacturers and distributors of Oxogluric acid. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Oxogluric acid 
Synonyms:
2-Ketoglutaric acid , 2-oxoglutaric acid , 2-oxopentanedioic acid , alpha-Ketoglutaric acid , Ketoglutaric acid , Oxoglurate , α-Ketoglutarate  
Cas Number:
328-50-7 
DrugBank number:
DB08845 
Unique Ingredient Identifier:
8ID597Z82X

General Description:

Oxogluric acid, identified by CAS number 328-50-7, is a notable compound with significant therapeutic applications. Oxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States. In the United States a phase I clinical trial is investigating whether oxogluric acid precursors found in nutritional supplements can benefit patients with the metabolic disorder propionic acidemia. Oxogluric acid is sold as a dietary supplement to athletes to improve their performance by helping to remove excess ammonia, but it is not officially approved for this indication and only experimental studies have shown a reduction in ammonia by oxogluric acid in hemodialysis patients. Physiologically, oxogluric acid acts in the Krebs cycle as an intermediate, is involved in transamination reactions during the metabolism of amino acids, forms glutamic acid by combining with ammonia, and reduces nitrogen by combining with it as well. Several experimental studies have also shown that administration of oxogluric acid helped attenuate the decreased synthesis of muscle protein that is often seen post-surgery.

Indications:

This drug is primarily indicated for: α-α-Ketoglutarate is not approved for any indication in the world but is an investigational drug in the United States. The potential indications for α-Ketoglutarate are in patients with the metabolic disorder propionic acidemia and in trauma patients with muscle loss. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Pharmacodynamics:

Oxogluric acid exerts its therapeutic effects through: All of the physiological roles of alpha-ketoglutarate have not been determined. What is known is that alpha-keotglutarate is involved in the Krebs cycle, transamination reactions, and promotes muscle synthesis. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Oxogluric acid functions by: The exact mechanisms of action for α-Ketoglutarate have not yet been elucidated. Some of α-Ketoglutarate’s actions include acting in the Krebs cycle as an intermediate, transamination reactions during the metabolism of amino acids, forming glutamic acid by combining with ammonia, and reducing nitrogen by combining with it as well. Concerning α-Ketoglutarate’s actions with ammonia, it is proposed that α-Ketoglutarate can help patients with propionic academia who have high levels of ammonia and low levels of glutamine/glutamate in their blood. Because endogenous glutamate/glutamine is produced from α-Ketoglutarate, propionic acidemia patients have impaired production of α-Ketoglutarate and supplementation of α-Ketoglutarate should improve the condition of these patients. Several other experimental studies have also shown that administration of α-Ketoglutarate in parenteral nutrition given to post-operative patients helped attenuate the decreased synthesis of muscle protein that is often seen after a surgery. This decreased muscle synthesis is speculated to be due to too low α-Ketoglutarate levels. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Classification:

Oxogluric acid belongs to the class of organic compounds known as gamma-keto acids and derivatives. These are organic compounds containing an aldehyde substituted with a keto group on the C4 carbon atom, classified under the direct parent group Gamma-keto acids and derivatives. This compound is a part of the Organic compounds, falling under the Organic acids and derivatives superclass, and categorized within the Keto acids and derivatives class, specifically within the Gamma-keto acids and derivatives subclass.

Categories:

Oxogluric acid is categorized under the following therapeutic classes: Acids, Acyclic, Dicarboxylic Acids, Glutarates, Keto Acids, Ketoglutaric Acids. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Oxogluric acid include:

  • Water Solubility: 100 g/l at 20 °C (68 °F)
  • Melting Point: 114 °C (237 °F)

Oxogluric acid is a type of Intermediates


Pharmaceutical intermediates are a crucial category within the API (Active Pharmaceutical Ingredient) industry. These chemical compounds play a vital role in the synthesis of APIs, serving as building blocks or precursor molecules in the manufacturing process. Pharmaceutical intermediates are designed to undergo specific chemical transformations, enabling the production of targeted APIs with desired properties.

These intermediates are typically produced through complex organic synthesis, involving various chemical reactions and purification steps. They are carefully developed and optimized to ensure high purity, stability, and safety, meeting stringent regulatory requirements for pharmaceutical use.

Pharmaceutical intermediates offer several advantages in API production. Firstly, they enable the efficient and cost-effective synthesis of APIs by providing a well-defined starting material. This reduces the need for expensive or hard-to-obtain raw materials, streamlining the overall manufacturing process. Secondly, intermediates allow for fine-tuning of the chemical reactions, optimizing the yield and quality of the final API. This control over the synthesis process enhances the consistency and reproducibility of pharmaceutical manufacturing.

Moreover, pharmaceutical intermediates facilitate the development of new APIs and drug formulations. By modifying the structure or functional groups of the intermediate molecules, researchers can explore different chemical pathways and create novel compounds with improved therapeutic efficacy, reduced side effects, or enhanced bioavailability.

In summary, pharmaceutical intermediates are essential components in API synthesis, enabling efficient and controlled production of pharmaceutical compounds. Their versatility and role in driving innovation make them indispensable in the pharmaceutical industry.